Skip to content

ClearPoint Neuro CLPT Common Stock Shares Subscriptions

Common Stock Shares Subscriptions at other companies

Terex logo
TerexTEX
214.5M-0.2%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
5.6M+5.2%
GCM Grosvenor Inc. logo
GCM Grosvenor Inc.GCMG
10.0%
DaVita logo
DaVitaDVA
69.2M-23.8%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
165.9M+4.3%
PNC Financial Services logo
PNC Financial ServicesPNC
77M-1.3%

Other financials

Income statement

See full
Revenue$12.1M+42.9%
Gross profit$7.8M+51.1%
Operating income-$8.5M-37.6%
Net income-$9.6M-58.5%
EPS (diluted)-$0.32-45.5%

Balance sheet

See full
Cash & equivalents$36.5M+195%
Total debt$63.6M+1,750%
Total equity$18.8M-5.7%
Total assets$93.4M+211%

Cash flow

See full
Operating cash flow-$8.0M-29.1%
CapEx$645.0K+252%
Free cash flow-$8.6M-35.5%

Valuation

See full
Market cap$538.61M+69.2%
Enterprise value$565.68M+82.9%
P/S13.3×+3.4×

Profitability

See full
Gross margin62.3%+1.1pp
Operating margin-65.2%-1.9pp
Net margin-71.6%+8.8pp
FCF margin-65.7%+269pp

Returns & leverage

See full
Return on equity-149.7%+4,074pp
Debt / equity3.4×+3.2×
Current ratio5.8×+2.3×

Where this comes from

Reported directly by ClearPoint Neuro in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesSubscriptions.

The official record: ClearPoint Neuro’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about ClearPoint Neuro's common stock shares subscriptions.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ClearPoint Neuro's common stock shares subscriptions?
ClearPoint Neuro (CLPT) reported common stock shares subscriptions of $5.54M in Q1 2026.
What does common stock shares subscriptions mean?
This metric represents the value of common stock shares that have been subscribed to but not yet fully issued or paid for as of the balance sheet date. It reflects future equity commitments or pending capital inflows from investors who have agreed to purchase shares. Monitoring this balance provides insight into potential future dilution and the company's ability to secure committed capital for operational or strategic expansion.